{"url":"https://lda.senate.gov/api/v1/filings/e89c7f70-e4c8-411a-a917-06104f688977/","filing_uuid":"e89c7f70-e4c8-411a-a917-06104f688977","filing_type":"Q4","filing_type_display":"4th Quarter - Report","filing_year":2013,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/e89c7f70-e4c8-411a-a917-06104f688977/print/","filing_document_content_type":"text/html","income":null,"expenses":"76358.00","expenses_method":"a","expenses_method_display":"Method A - Reporting amounts using LDA definitions only","posted_by_name":"Mark Cooke, Sr. Director Government Affairs","dt_posted":"2014-01-20T14:30:29.267000-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1 Park Place, #450","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"ANNAPOLIS","registrant_state":"MD","registrant_zip":"21401","registrant":{"id":285370,"url":"https://lda.senate.gov/api/v1/registrants/285370/","house_registrant_id":36974,"name":"PHARMATHENE, INC","description":"Biotechnology research, development and manufacturing. Biodefense vaccines/therapeutics","address_1":"1 Park Place, #450","address_2":null,"address_3":null,"address_4":null,"city":"ANNAPOLIS","state":"MD","state_display":"Maryland","zip":"21401","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"FRANCESCA COOK","contact_telephone":"+1 410-269-2515","dt_updated":"2022-04-06T16:08:24.318364-04:00"},"client":{"id":176005,"url":"https://lda.senate.gov/api/v1/clients/176005/","client_id":12,"name":"PHARMATHENE, INC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"MD","state_display":"Maryland","country":"US","country_display":"United States of America","ppb_state":"MD","ppb_state_display":"Maryland","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2009-01-21"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"FY-2014 Appropriations Continuing Resolution ; Inclusion of anomalies for funding for Biomedical Advanced Research and Development Authority (BARDA) and funding for Project BioShield Special Reserve Fund (SRF) to fund medical countermeasure procurement in the Startegic National Stockpile. Funding for biodefense (BARDA/SRF) in the FY-2014 Appropriations Act.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":17384,"prefix":null,"prefix_display":null,"first_name":"FRANCESCA","nickname":null,"middle_name":null,"last_name":"COOK","suffix":null,"suffix_display":null},"covered_position":"Sr. VP Policy and Government Affairs","new":false},{"lobbyist":{"id":44682,"prefix":"mr","prefix_display":"MR.","first_name":"MARK","nickname":null,"middle_name":"EDWARD","last_name":"COOKE","suffix":null,"suffix_display":null},"covered_position":"Sr. Director Government Affairs","new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}